BioSpace News Archive

BioCardia®, Inc. announced it will report its financial results for the the three months ended March 31, 2024 and provide a corporate update by conference call on Tuesday, May 14, 2024 at 4:30 PM ET.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, reported business highlights and financial results for the first quarter ending March 31, 2024.

Wave Life Sciences Ltd., a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer.

Aura Biosciences, Inc. reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, announced financial and operating results for the first quarter ended March 31, 2024, and provided a corporate update.

ASLAN Pharmaceuticals announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.

Q32 Bio Inc., a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, reported financial results for the quarter ended March 31, 2024 and provided recent corporate updates.

Oncolytics Biotech® Inc., a leading clinical-stage company specializing in immunotherapy for oncology, will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory and ethics approvals.

Evogene Ltd., a leading computational biology company targeting to revolutionize life-science product discovery and development, announced that it will release its financial results for the first quarter of 2024, on Thursday, May 23, 2024.

Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, joined Flagship Pioneering in announcing a research collaboration with Novo Nordisk to develop up to two next-generation therapeutics for obesity management.